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in previously healthy white patients 
from Germany differ from previous-
ly published cases. These 2 patients 
were not of Asian ethnicity and had no 
travel history, no contact with persons 
in a high-risk group (10), and no com-
mon risk factors such as malignancy 
(8); however, 1 patient had type-2 dia-
betes. K. pneumoniae liver abscesses 
might be an emerging problem with 
global spread. Although initial radio-
graphic findings might more common-
ly indicate metastasis than abscesses, 
differential diagnosis of liver lesions 
should include K. pneumoniae– 
induced abscesses. 
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Hepatitis E Virus 
and Implications  
for Blood Supply 
Safety, Australia
To the Editor: Hepatitis E virus 
(HEV) is an emerging public health 
concern for industrialized countries 
(1). Although HEV infection has been 
associated with travel to countries 
where the virus is endemic, cases of 
autochthonous HEV are increasing 
(2). Detection of HEV RNA in blood 
donations in the United Kingdom, 
Germany, the Netherlands, Japan, 
and China and accumulating reports 
of HEV transmitted through blood 
transfusion highlight the potential 
risk this virus poses to blood supply 
safety (1–4).
In Australia, where most HEV 
infections are associated with travel 
(5), an average of 25 HEV cases oc-
curred each year during 1999–2013 
(http://www9.health.gov.au/cda/
source/rpt_3.cfm). HEV infection is 
nationally notifiable in Australia, but 
the presence of subclinical infections 
and the lack of recent seroprevalence 
studies have prevented the accurate 
estimation of HEV incidence and pop-
ulation exposure. Thus, we examined 
HEV seroprevalence in a cohort of 
Australian blood donors, assessed risk 
factors for exposure, and used the data 
to examine the effectiveness of current 
blood safety strategies for the manage-
ment of HEV in Australia.
Plasma samples (n = 3,237) were 
collected from donors during August–
September 2013. Information on age, 
sex, state of residence, new/repeat do-
nor status, and overseas travel disclo-
sure was obtained. Details of any rele-
vant blood donation deferral (malaria, 
diarrhea) applied on previous donation 
attempts were also collected. Applica-
tion of a specific malaria deferral code 
is routine for donors disclosing travel 
to a malaria-endemic country, and a 
diarrhea deferral applies when a donor 
reports having had diarrhea (of viral or 
unknown cause) 1 week before any at-
tempted donation. 
All samples were tested for HEV 
IgG by using the Wantai HEV-IgG 
ELISA (Beijing Wantai Biologic Phar-
macy Enterprise Co., Ltd, Beijing, 
China). Positive samples were tested 
for HEV IgM by using the Wantai 
HEV-IgM ELISA and for HEV RNA 
by using a prototype transcription-
mediated amplification assay (Hologic 
Inc., San Diego, CA, USA).
Of 3,237 samples, 194 (5.99%) 
were positive for HEV IgG (95% CI 
5.18–6.81). Compared with estimates 
1These	 authors	 contributed	 equally	 to	 this	
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from previous studies that used the 
Wantai ELISA (6–9), our estimate is 
comparable to those reported from 
Scotland (4.7%) and New Zealand 
(4.2%) but lower than those from the 
United States (18.8%) and southwest-
ern France (52.5%). Considerable de-
bate exists regarding the sensitivity and 
specificity of HEV detection methods 
(2,10); however, on the basis of stud-
ies in France and the United Kingdom 
(9,10), we believe that the measured 
seroprevalence in our study is accurate.
Our findings showed an increased 
seroprevalence of HEV associated 
with previous malaria deferral, diar-
rhea deferral, and age (multivariate 
logistic regression) (Table), the latter 
of which is consistent with previous 
findings (9). IgG seropositivity was 
also higher (7.73%) in donors who 
had traveled to a malaria-endemic 
country. HEV is often endemic to 
malaria-endemic countries (http://
wwwnc.cdc.gov/travel/yellowbook/ 
2014); however, the HEV exposure 
status of travelers is unknown before 
departure, so the exact place of expo-
sure cannot be determined. Further-
more, 3.37% of donors in our study 
had evidence of previous HEV expo-
sure; these donors had not reported 
travel outside Australia, so they may 
have acquired HEV locally. Because 
subclinical HEV infection is possible, 
persons infected locally may not be 
identified by the current donor screen-
ing questionnaire and thus pose a po-
tential risk to blood supply safety.
Detection of HEV IgM in 4 
(2.06%) of the 194 samples from IgG-
positive donors indicates the donors had 
been recently exposed to HEV (95% CI 
0.06–4.06). All 4 donors had traveled 
overseas; 3 reported travel to malaria-
endemic countries. HEV RNA was not 
detected in any of the HEV IgG–posi-
tive samples. Although it is encourag-
ing that HEV nucleic acid was not de-
tected, the sample size is insufficient 
to accurately determine the true rate of 
HEV RNA carriage among donors in 
this study; a larger study is planned.
Management strategies to safe-
guard the Australian blood supply 
against transfusion-transmitted HEV 
are based on donor selection guide-
lines. To identify donors with possible 
bacteremia/viremia, including HEV, 
blood donation staff members ask do-
nors several medical, behavioral, and 
travel-based questions before dona-
tion. These include questions relat-
ing to general wellness, sex practices, 
gastric upset, diarrhea, abdominal 
pain, and vomiting within the previous 
week. In addition, for 4 months after 
a donor’s return from travel to a ma-
laria-endemic country, donations are 
 
Table.	HEV	(IgG)	seroprevalence,	and	risk	factors	for	exposure,	in	Australian	blood	donors* 
Risk	factor 
No.	
tested 
HEV	IgG	seropositive  Univariate	analysis  Multivariate	analysis 
No. %	(95%	CI) OR	(95%	CI) p	value OR	(95%	CI) p	value 
Sex          
 F 1,453 78 5.37	(4.21–6.53)  † †  – – 
 M 1,784 116 6.50	(5.36–7.65)  1.23	(0.91–1.65) 0.177  – – 
Age,	y      0.000   0.000 
 <25 564 14 2.48	(1.20–3.77)  † †  † † 
 25–34 569 13 2.28	(1.06–3.51)  0.92	(0.43–1.98) 0.827  0.82	(0.38–1.77) 0.61 
 35–44 510 22 4.31	(2.55–6.08)  1.77	(0.89–3.5) 0.100  1.72	(0.87–3.42) 0.118 
 45–54 666 40 6.01	(4.20–7.81)  2.51	(1.35–4.66) 0.004  2.43 (1.30–4.52) 0.005 
 55–64 673 68 10.10	(7.83–12.38)  4.41	(2.46–7.94) 0.000  4.18	(2.32–7.54) 0.000 
 ≥65 255 37 14.51	(10.19–18.83)  6.67	(3.54–12.58) 0.000  6.09	(3.21–11.55) 0.000 
State	of	residence      0.580  – – 
 ACT 406 25 6.16	(3.82–8.50)  † †  – – 
 NSW 405 23 5.68	(3.42–7.93)  0.92	(0.51–1.64) 0.773  – – 
 NT 407 26 6.39	(4.01–8.76)  1.04	(0.59–1.83) 0.892  – – 
 QLD 402 18 4.48	(2.46–6.50)  0.71	(0.38–1.33) 0.289  – – 
 SA 404 32 7.92	(5.29–10.55)  1.31	(0.76–2.25) 0.328  – – 
 TAS 401 20 4.99	(2.86–7.12)  0.80	(0.43–1.46) 0.800  – – 
 VIC 411 23 5.60	(3.37–7.82)  0.90	(0.50–1.62) 0.733  – – 
 WA 401 27 6.73	(4.28–9.19)  1.10	(0.63–1.93) 0.739  – – 
Overseas	travel          
 No 416 14 3.37	(1.63–5.10)  † †  † † 
 Yes 2,821 180 6.38	(5.48–7.28)  1.96	(1.12–3.40) 0.017  1.24	(0.69–2.25) 0.471 
Previous	malaria	deferral          
 No 1,684 74 4.39	(3.42–5.37)  † †  † † 
 Yes 1,553 120 7.73	(6.40–9.06)  1.82	(1.35–2.45) 0.000  1.80	(1.31 2.47) 0.000 
Previous	diarrhea deferral          
 No 3,179 185 5.82	(5.01–6.63)  † †  † † 
 Yes 58 9 15.52	(6.20–24.84)  2.97	(1.44	– 6.14) 0.003  2.55	(1.22–5.33) 0.013 
Donor status          
 New 307 13 4.23	(1.98–6.49)  † †  – – 
 Repeat 2,930 181 6.18	(5.31–7.05)  1.49	(0.84–2.65) 0.175  – – 
*ACT,	Australian	Capital	Territory;	HEV,	hepatitis	E	virus;	NSW,	New	South	Wales;	NT,	Northern	Territory;	OR,	odds	ratio;	QLD,	Queensland;	SA,	South	
Australia;	TAS,	Tasmania;	VIC,	Victoria;	WA,	Western	Australia;	–,	indicates	factor	was	not	included	in	multivariate	analyses. 
†Reference group used in respective analyses. 
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restricted to plasma for fractionation. 
Some protection against blood dona-
tions from HEV-infected persons may 
occur because HEV and malaria are co-
endemic to many countries. Our find-
ings showed a higher HEV seropreva-
lence among donors with prior malaria 
or diarrhea deferrals; thus, malaria- and 
diarrhea-related screening questions 
may reduce contributions from donors 
with travel-associated HEV infection.
Our findings showed HEV expo-
sure in travelers and nontravelers, sug-
gesting the possibility of imported and 
locally acquired HEV in Australia. Pri-
or HEV exposure was higher in donors 
who were temporarily excluded from 
donating blood on previous donation 
attempts, suggesting the current man-
agement strategy in Australia is par-
tially effective in minimizing any risk 
of HEV transmission through blood 
transfusion. However, the presence of 
HEV IgG in donors who reported no 
overseas travel and/or no prior related 
deferrals, coupled with the knowledge 
that asymptomatic infection is possible, 
suggests that additional safety precau-
tions may be warranted.
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Helicobacter  
cinaedi Infection  
of Abdominal Aortic 
Aneurysm, Japan
To the Editor: Infected ab-
dominal aortic aneurysm (IAAA) 
is uncommon, but life-threatening; 
the mortality rate ranges from 25% 
to 30% (1,2). Identification of the 
pathogen is essential for diagno-
sis and treatment. Previous studies 
have shown that species of the gen-
era Salmonella, Staphylococcus, and 
Streptococcus are the most common 
pathogens associated with IAAA, but 
a causative organism is not identified 
in 14%–40% of patients (1,2). He-
licobacter cinaedi has mainly been 
isolated from immunocompromised 
patients with bacteremia, cellulitis, 
and septic arthritis (3,4). Here, we 
report 3 cases of IAAA caused by H. 
cinaedi detected by 16S ribosomal 
RNA (16S rRNA) gene analysis.
The 3 patients (case-patients 1–3) 
were referred to Tohoku University 
